These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35920701)

  • 21. [Psoriasis and bullous pemphigoid].
    Bork K
    Hautarzt; 1987 Jun; 38(6):348-51. PubMed ID: 3308771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
    Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two cases with bullous pemphigoid relapsed after using interleukin-17A inhibitors for psoriasis: A paradoxical reaction.
    Wang R; Wang A; Wang M
    J Dermatol; 2023 Jul; 50(7):956-959. PubMed ID: 36880309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis.
    Wang G; Hu X; Han S; Zhou M
    J Dermatolog Treat; 2024 Dec; 35(1):2366535. PubMed ID: 38945532
    [No Abstract]   [Full Text] [Related]  

  • 25. [Anti-p200 pemphigoid: a spectacular response to dapsone].
    Munsch C; Prey S; Joly P; Meyer N; Lamant L; Livideanu C; Viraben R; Paul C
    Ann Dermatol Venereol; 2011 Nov; 138(11):739-42. PubMed ID: 22078034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Psoriasis-pemphigoid association. Description of a case].
    Di Silverio A; Vignini M; Gabba P; Bellosta M; Brandozzi G
    G Ital Dermatol Venereol; 1989; 124(7-8):359-61. PubMed ID: 2697684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis.
    Deepak HB; Prince SE; Deshpande P
    Indian J Pharmacol; 2022; 54(3):183-193. PubMed ID: 35848689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAK inhibitors in chronic plaque psoriasis: What is known so far.
    Plachouri KM; Georgiou S
    Drugs Today (Barc); 2020 Feb; 56(2):151-163. PubMed ID: 32163530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythrodermic psoriasis with bullous pemphigoid: combination treatment with methotrexate and compound glycyrrhizin.
    Si X; Ge L; Xin H; Cao W; Sun X; Li W
    Diagn Pathol; 2014 May; 9():102. PubMed ID: 24885087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.
    Alexandre M; Bohelay G; Gille T; Le Roux-Villet C; Soued I; Morin F; Caux F; Grootenboer-Mignot S; Prost-Squarcioni C
    Front Immunol; 2022; 13():874108. PubMed ID: 35514989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Local and Sustained Baricitinib Delivery to the Skin through Injectable Hydrogels Containing Reversible Thioimidate Adducts.
    Wang LL; Tuohy S; Xu KL; Nace A; Yang R; Zheng Y; Burdick JA; Cotsarelis G
    Adv Healthc Mater; 2024 May; 13(12):e2303256. PubMed ID: 38207170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pustular psoriasis associated with bullous pemphigoid with fluctuating anti-BP180 antibody titre according to the condition of pustular lesions.
    Otani Y; Hayashi S; Kaneko Y; Koike M; Gommori T; Hamasaki Y; Igawa K
    Eur J Dermatol; 2021 Feb; 31(1):107-109. PubMed ID: 33648907
    [No Abstract]   [Full Text] [Related]  

  • 33. Guselkumab-associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature.
    Burlando M; Capurro N; Herzum A; Cozzani E; Parodi A
    Dermatol Ther; 2022 Jan; 35(1):e15207. PubMed ID: 34791777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Symptomatic elevation creatine kinase following treatment of rheumatoid arthritis with baricitinib.
    Anjara P; Jiang M; Mundae M
    Clin Rheumatol; 2020 Feb; 39(2):613-614. PubMed ID: 31782014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of baricitinib in patients with moderate-to-severe refractory alopecia areata in real world: An open-label, single-center study.
    Bi L; Wang C; Du Y; Su T; Zhao M; Lin X; Fan W; Sun W
    J Cosmet Dermatol; 2024 Apr; 23(4):1417-1421. PubMed ID: 38116864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pemphigoid Diseases as a Sign of Active Psoriasis: A Case Report and Brief Review.
    Iskandarli M; Gerceker Turk B; Yaman B; Ozturk G
    Dermatology; 2015; 231(4):319-21. PubMed ID: 26278716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Psoriasis and pemphigoid (author's transl)].
    Olmos L; de Diego V
    Dermatologica; 1981; 163(1):105-12. PubMed ID: 7024004
    [No Abstract]   [Full Text] [Related]  

  • 38. Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: A single-center retrospective review.
    Wang M; Lehman JS; Camilleri MJ; Drage LA; Wieland CN
    J Am Acad Dermatol; 2019 Aug; 81(2):472-479. PubMed ID: 30928465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of bullous pemphigoid limited to psoriatic plaques.
    Kobayashi TT; Elston DM; Libow LF; David-Bajar K
    Cutis; 2002 Nov; 70(5):283-7. PubMed ID: 12469782
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.